These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 3493329)
21. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain. Fuller RW; Robertson DW; Hemrick-Luecke SK J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775 [TBL] [Abstract][Full Text] [Related]
22. Behavioral and biochemical changes following acute administration of MPTP and MPP+. Tadano T; Satoh N; Sakuma I; Matsumura T; Kisara K; Arai Y; Kinemuchi H Life Sci; 1987 Mar; 40(13):1309-18. PubMed ID: 2436017 [TBL] [Abstract][Full Text] [Related]
23. Pharmacological effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine receptor system. Lau YS; Fung YK Brain Res; 1986 Mar; 369(1-2):311-5. PubMed ID: 3486026 [TBL] [Abstract][Full Text] [Related]
24. Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. Sundström E; Jonsson G Eur J Pharmacol; 1985 Apr; 110(3):293-9. PubMed ID: 3874083 [TBL] [Abstract][Full Text] [Related]
25. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced dopamine D2 receptor hypersensitivity in the mouse is transient. Peroutka SJ; DeLanney L; Irwin I; Ison PJ; Ricaurte G; Schlegel JR; Langston JW Res Commun Chem Pathol Pharmacol; 1985 May; 48(2):163-71. PubMed ID: 3875136 [TBL] [Abstract][Full Text] [Related]
26. 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl)pyridine: studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Finnegan KT; Irwin I; Delanney LE; Ricaurte GA; Langston JW J Pharmacol Exp Ther; 1987 Sep; 242(3):1144-51. PubMed ID: 3498815 [TBL] [Abstract][Full Text] [Related]
27. Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Perry TL; Hansen S; Jones K Neurosci Lett; 1987 Feb; 74(2):217-20. PubMed ID: 3494963 [TBL] [Abstract][Full Text] [Related]
28. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment decreases dopamine and increases lipofuscin in mouse retina. Mariani AP; Neff NH; Hadjiconstantinou M Neurosci Lett; 1986 Dec; 72(2):221-6. PubMed ID: 3492691 [TBL] [Abstract][Full Text] [Related]
29. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice. Leng A; Mura A; Hengerer B; Feldon J; Ferger B Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025 [TBL] [Abstract][Full Text] [Related]
30. Manipulation of glutathione contents fails to alter dopaminergic nigrostriatal neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Perry TL; Yong VW; Jones K; Wright JM Neurosci Lett; 1986 Oct; 70(2):261-5. PubMed ID: 3490637 [TBL] [Abstract][Full Text] [Related]
31. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogues on the dopaminergic nigrostriatal pathway in mice. Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC Neurosci Lett; 1985 Jul; 58(1):133-7. PubMed ID: 3876523 [TBL] [Abstract][Full Text] [Related]
32. Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. Hadjiconstantinou M; Neff NH J Neurochem; 1988 Oct; 51(4):1190-6. PubMed ID: 3262149 [TBL] [Abstract][Full Text] [Related]
33. The effects of intranasal infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) upon catecholamine concentrations within olfactory bulbs and corpus striatum of male mice. Dluzen DE; Kefalas G Brain Res; 1996 Nov; 741(1-2):215-9. PubMed ID: 9001725 [TBL] [Abstract][Full Text] [Related]
34. Changes in Striatal Medium Spiny Neuron Morphology Resulting from Dopamine Depletion Are Reversible. Witzig VS; Komnig D; Falkenburger BH Cells; 2020 Nov; 9(11):. PubMed ID: 33182316 [TBL] [Abstract][Full Text] [Related]
35. In vivo effect of MPTP on monoamine oxidase activity in mouse striatum. Melamed E; Youdim MB; Rosenthal J; Spanier I; Uzzan A; Globus M Brain Res; 1985 Dec; 359(1-2):360-3. PubMed ID: 3878183 [TBL] [Abstract][Full Text] [Related]
36. Effect of chronic oral nicotine on dopaminergic function in the MPTP-treated mouse. Sershen H; Hashim A; Wiener HL; Lajtha A Neurosci Lett; 1988 Nov; 93(2-3):270-4. PubMed ID: 3266524 [TBL] [Abstract][Full Text] [Related]
37. Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment. Yong VW; Perry TL; Krisman AA Neurosci Lett; 1986 Jan; 63(1):56-60. PubMed ID: 3485266 [TBL] [Abstract][Full Text] [Related]
38. Persistent depletion of striatal dopamine and its metabolites in mice by TMMP, an analogue of MPTP. Fuller RW; Hemrick-Luecke SK J Pharm Pharmacol; 1987 Aug; 39(8):667-9. PubMed ID: 2888865 [TBL] [Abstract][Full Text] [Related]
39. The neurotoxicant MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) increases glial fibrillary acidic protein and decreases dopamine levels of the mouse striatum: evidence for glial response to injury. Reinhard JF; Miller DB; O'Callaghan JP Neurosci Lett; 1988 Dec; 95(1-3):246-51. PubMed ID: 3265770 [TBL] [Abstract][Full Text] [Related]
40. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF. Elsworth JD; Deutch AY; Redmond DE; Sladek JR; Roth RH Brain Res; 1987 Jul; 415(2):293-9. PubMed ID: 3496938 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]